Gateway to Think Tanks
来源类型 | Article |
规范类型 | 评论 |
Generics substitution, equivalence standards, and international oversight: Complex issues facing the FDA | |
Roger Bate; Aparna Mathur; Dinesh Thakur | |
发表日期 | 2015-12-14 |
出版年 | 2015 |
语种 | 英语 |
摘要 | Abstract: The regulations for assessing the quality of generic drugs and their bioequivalence to innovator products are outdated and need to be substantially modernized. There are multiple reasons why these changes are needed, including: (i) the regulations remain largely unchanged since the passage of the Hatch–Waxman Act in 1984; (ii) medication therapies have become substantially more complex over the three decades since the passage of the Act; (iii) a switch from an innovator drug to a generic drug, or switching from one generic to another, is not a benign process – there is substantial clinical professional judgment involved and in some instances these decisions should be better informed; and (iv) pharmaceutical ingredients for finished products, whether innovator or generic, are from multiple sources of supply, adding variability in their production, and which may not be accounted for in specification tolerances. When these elements are viewed together, they clearly suggest that more transparency of responsible manufacturers in product labels and updated standards for bioequivalence are required. For subscribers to Trends in Pharmacological Sciences, the paper is available here. |
主题 | Economics ; Public Economics |
标签 | drug industry ; FDA ; generic drugs ; Pharmaceuticals |
URL | https://www.aei.org/articles/generics-substitution-equivalence-standards-and-international-oversight-complex-issues-facing-the-fda/ |
来源智库 | American Enterprise Institute (United States) |
资源类型 | 智库出版物 |
条目标识符 | http://119.78.100.153/handle/2XGU8XDN/259795 |
推荐引用方式 GB/T 7714 | Roger Bate,Aparna Mathur,Dinesh Thakur. Generics substitution, equivalence standards, and international oversight: Complex issues facing the FDA. 2015. |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。